Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

Published: Tuesday, May 20, 2025 at 8:34 pm

Novavax Vaccine Gets Limited FDA Approval After Delay, Faces Further Scrutiny

Novavax has finally received full FDA approval for its COVID-19 vaccine, Nuvaxovid, but the news comes with significant caveats. After a delay, the approval restricts the vaccine's use to individuals aged 65 and older, and those aged 12-64 with underlying medical conditions that put them at high risk of severe illness. This limited scope reflects a cautious approach, potentially influenced by evolving perspectives within federal health agencies.

The FDA's decision is particularly noteworthy as it comes amidst broader discussions about the future of COVID-19 vaccination strategies. The FDA is set to outline its approach to COVID vaccination, potentially impacting future regulatory requirements for vaccine approvals. Additionally, advisors to the CDC are debating whether yearly COVID vaccines should be recommended for everyone or only high-risk individuals.

While the full approval is a positive step for Novavax, the company faces additional hurdles. The FDA requires post-marketing studies to assess potential links between the vaccine and heart conditions like myocarditis. These studies will likely involve tracking thousands of individuals, adding to the company's workload.

Despite the restrictions and added requirements, analysts view the approval as a win for Novavax. The company is now preparing for commercial delivery of the vaccine this fall, in partnership with Sanofi. This partnership, including a $1.2 billion licensing deal, is expected to bolster Novavax's market position. The approval also triggered a $175 million milestone payment from Sanofi. The focus on the 65+ age group, which represents a significant portion of COVID-19 vaccinations, could still provide a viable market for Novavax.

BNN's Perspective: While the FDA's cautious approach is understandable given the evolving scientific understanding of COVID-19 and vaccine safety, the restrictions on Novavax's vaccine could limit its impact. It's crucial to balance public health concerns with the need for accessible vaccine options, especially for those who may prefer or benefit from a non-mRNA vaccine. The ongoing discussions about vaccination strategies highlight the dynamic nature of this public health challenge.

Keywords: Novavax, Nuvaxovid, FDA approval, COVID-19 vaccine, vaccine restrictions, myocarditis, Sanofi, vaccine market, post-marketing studies, underlying medical conditions, elderly, vaccination strategy, mRNA vaccines, CDC, health agencies.

Full Story